Biocryst Pharmaceuticals is committed to developing innovative drugs to treat various rare and serious diseases, with a focus on key areas such as virology, oncology, and orphan diseases. Their goal is clear: to provide more effective and convenient treatments to improve patients' lives and address existing medical gaps. They particularly stand out for their research on orally administrable drugs, offering a more convenient way for patients to take their medication.
Our interest in Biocryst Pharmaceuticals was strongly influenced by their research program on hereditary angioedema (HAE), a rare and potentially life-threatening disease. We closely followed their application for approval from the FDA and the Japanese Pharmaceuticals and Medical Devices Agency for oral berotralstat, a daily prophylactic treatment for HAE, with potential approval expected in 2020.
After thoroughly analyzing the Phase 3 clinical trial results of berotralstat and being convinced of its effectiveness, we decided to invest in Biocryst Pharmaceuticals. Their drug pipeline, including their factor D inhibitor, also impressed us and bolstered our confidence in the company. On April 22, 2020, we made the decision to acquire our first BCRX shares, marking the beginning of a new and promising investment journey that turned out to be unforgettable.
Account 1
Here is an overview of the transactions made on account 1, ultimately resulting in a significant profit of +$66870,01.
Account 2
Here is an overview of the transactions made on account 2, ultimately resulting in a significant profit of +$50948,30.
Account 3
Here is an overview of the transactions made on account 3, ultimately resulting in a significant profit of +$3601.97.
Account 4
Here is an overview of the transactions made on account 4, ultimately resulting in a significant profit of +$1138.93.
Account 5
Here is a summary of the transactions made on account 5, ultimately resulting in a significant profit of +$37563,79 ($59,977.05 - $8.95 - $5,598.55 - $12,893.35 - $2,036.91 - $1,875.50). It's important to note that when I left Canada, I transferred trading accounts, which is why the buying and selling order lines for account 5 may appear different. To be precise, two other separate accounts were transferred to a single account, account 5.
Outcome of BCRX investment: +$160123.00.
Moral: The first significant profit is extremely gratifying and brings me a step closer to my personal goal. From here, it's crucial to stay humble and not let excitement overshadow sound judgment. Additionally, maintaining a high level of analysis is crucial to identifying the next opportunity in the biotech sector. Keeping a level head is essential.
Comments